Cystic Fibrosis Prevalence to Raise by 2030

New report by leading data analytics company, GlobalData predicts the prevalence of cystic fibrosis in 2030.

Prevalence of diagnosed cases of cystic fibrosis (CF) in the US, France, Germany, Italy, Spain, the UK and Canada are projected to increase from over 79,000 in 2020 to nearly 84,000 in 2030, with an annual growth rate (AGR) of 0.52%, according to GlobalData, a leading data and analytics company.

Cystic fibrosis is a progressive, genetic disease that causes persistent lung infections and limits the ability to breathe over time.

Cystic Fibrosis - Symptoms, Causes, Diagnosis, Treatment, Support Groups
Cystic fibrosis is a genetic disease involving the mucus and sweat glands and the medical world has still to find its cure

‘Diagnosed cases of cystic fibrosis will be near 84,000 by 2030 . ’

The company’s latest report reveals that in 2030, the US will have the highest number of diagnosed prevalent cases of CF due to projected increase in the population through 2030 whereas Spain will have the lowest number of cases.

Shaina Stacy, PhD, Senior Epidemiologist at GlobalData, says: “The rise in diagnosed prevalent cases is attributable to increases in the proportion of adults living with CF, significant and increasing historical trends in prevalence, and changes in the underlying population demographics”.

Advancements in CF treatment over the last several decades such as widespread implementation of newborn screening programs have made the patients to start treatment earlier and extend their life expectancy.

Respiratory Diseases - Diseases of the Human Respiratory System
Respiratory diseases affect any part of the respiratory system. Some of the lung diseases like chronic obstructive pulmonary disease can lead to respiratory failure.

All these countries have established national CF patient registries to drive efforts in CF education, care, and research. Although there is currently no cure for CF, additional research and drug development will continue to improve the quality of life and longevity of people with CF.

Cystic Fibrosis Patients With Specific Mutations To Benefit From New Drug
A new combination drug for cystic fibrosis has been approved by the USFDA in people ages 12 and older that can treat the underlying cause of the disease.

Source-Medindia

Now a Wearable Sweat Sensor Band is Here to Help Diagnose Cystic Fibrosis
A wristband-type wearable sweat sensing band can help in the quick analysis of sweat and easy diagnosis of conditions like cystic fibrosis.